Outcomes of Bioprosthetic Valve Fracture in Patients Undergoing Valve-in-Valve TAVR: @JACCJournals
Many years of collecting these cases: amazing work @AdnanChatriwala ππ
Summary in 15 short bullets
πππ
1/ This study represents the largest cohort of patients who underwent bio prosthetic valve fracture (BVF) as an adjunct to valve in valve (VIV) #TAVR.
2/ BVF is commonly performed as an adjunct to VIV TAVR, particularly in patients with small surgical valves (30% frequency).
3/ However, institutional volumes of attempted BVF are relatively low, with fewer than 35 hospitals performing 5 or more BVF procedures per year.
4/ In adjusted analyses, in-hospital and 30-day mortality, cardiac death, all-cause death or stroke, and life-threatening bleeding were higher in patients who underwent VIV TAVR with attempted BVF compared with those who underwent VIV TAVR without fracture.
5/ Nevertheless, these differences were numerically smaller and not statistically significant in patients who underwent BVF after THV implantation, compared with patients in whom BVF was not attempted, suggesting that procedural technique plays an important role in safety.
6/ When clinically indicated, BVF should be performed after, rather than before, THV implantation.
7/ BVF in the setting of VIV TAVR optimizes THV expansion and can mitigate PPM, which is associated with higher mortality after VIV TAVR.
8/ However, the longer-term effect of BVF on clinical outcomes remains unknown.
9/ One concern with BVF performed prior to VIV TAVR is the potential for surgical valve leaflet injury causing acute severe valvular regurgitation and hemodynamic compromise for a period of time until a competent THV can be implanted.
10/ Other complications that could be directly linked to BVF, such as annular rupture, aortic dissection, and coronary occlusion, were rare (<1%).
11/ Interestingly, despite the higher rate of observed complications in patients with attempted BVF, average procedure time was not higher.
12/ Although it appears that BVF performed after THV implantation is the safer option, the question of whether the smaller hazard observed with this technique could be offset by longer-term clinical benefits needs prospective confirmation.
13/ Prior bench testing has demonstrated that most, but not all, surgical valves can be fractured.
14/ Surgical valves vary greatly in their composition, and the threshold at which a valve fractures is dependent on the composition of the valve, and the size of the balloon being used for BVF, and the balloon pressure required to fracture may exceed 20 atm.
15/ In conclusion: The use of BVF as an adjunct to VIV TAVR with SAPIEN 3 & SAPIEN 3 Ultra valves is associated with a higher risk of mortality, excess bleeding, modest reduction in echocardiographic valve gradient, and gain in valve area, when compared with no fracture.
Evaluation and Management of Pulmonary Hypertension in Noncardiac Surgery: A Scientific Statement From the American Heart Association: @CircAHA
Here are few points to summarize
ππ
1/ Pulmonary hypertension (PH) is a group of disorders that result in an elevation in blood pressure in the pulmonary arteries (mean pulmonary artery [PA] pressure [mPAP] >20 mm Hg) and is associated with an increased risk of death.
2/ PH is increasing in prevalence due to an aging population, rising prevalence of heart and lung disease, and improved PH survival with targeted therapies.
Management of Stable Angina in the Older Adult Population: @CircIntv
- This time I get to summarize our work led by my friend @MichaelGNanna
20-point summary π§΅
πππ
1/ Stable Ischemic Heart Disease (SIHD) is a major cause of morbidity, mortality, and disability in older adults, with those aged β₯75 making up 30% of patients affected in the US.
2/ Medical therapy is the preferred initial management option for most patients with stable SIHD, with revascularization reserved for high-risk anatomy or breakthrough symptoms.
Anticoagulation Strategies in Non-Critically Ill Patients Hospitalized with COVID-19: A Randomized Clinical Trial: @JACCJournals
From the FREEDOM COVID Anticoagulation Strategy Randomized Trial Investigators
Here is summary πππ
β‘οΈIn this large-scale randomized trial, the aim was to compare the safety and effectiveness of low-molecular-weight heparin and direct-acting oral anticoagulant with standard thromboprophylaxis in non-critically ill hospitalized patients with COVID-19.
β‘οΈDifference between groups in the incidence of the 30-day primary outcome in patients treated with therapeutic-dose anticoagulation compared with prophylactic-dose anticoagulation did not reach statistical significance.